Role of CDK4/6 inhibitors in targeting Rb proficient small cell lung cancer

Virginia Corbett,Triparna Sen,Aman Chauhan

DOI: https://doi.org/10.21037/tlcr-23-337

2024-01-31

Translational Lung Cancer Research

Abstract:Virginia Corbett 1 , Triparna Sen 2 , Aman Chauhan 3 1 Division of Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3 Division of Medical Oncology, Department of Internal Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA Comment on: Febres-Aldana CA, Chang JC, Ptashkin R, et al . Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Clin Cancer Res 2022;28:4702-13. Keywords: Small cell lung cancer (SCLC); CDK4/6 inhibitors; drug development; targeted therapies Submitted May 25, 2023. Accepted for publication Dec 26, 2023. Published online Jan 18, 2024. doi: 10.21037/tlcr-23-337 Small cell lung cancer (SCLC) is a high-grade neuroendocrine carcinoma, and remains one of the deadliest cancers with limited therapeutic options, resulting in a dismal 5-year overall survival of 5% (1). This continued lack of treatment progress in SCLC contrasts with non-small cell lung cancer (NSCLC), where remarkable advances have been made, especially with targeted drugs for molecularly defined patient subsets (e.g., EGFR mutated cancers; ALK and ROS1 fusions) (2). Although recent clinical trials have shown that immunotherapy with PD-L1 blockade can improve survival in patients with extensive stage SCLC (3,4), the benefits remain restricted to a minority of patients and are less impressive than the effect of immunotherapy in other cancer types. SCLC is characterized by bi-allelic inactivation of two major tumor suppressor genes, TP53 and RB1 , and lack of any actionable driver mutations. One third of patients can exhibit high tumor mutation burden. Recent investigations have mainly focused on characterization of biological underpinnings of SCLC. Major advances include the identification of the role of tumor heterogeneity and lineage plasticity (5), the discovery of molecular subgroups defined by differential expression of transcription factors (6-8), and potential subtype-specific therapeutic vulnerabilities. SCLC is now divided into four major subgroups—SCLC-A—defined by upregulated ASCL1, SCLC-N with upregulated NEUROD1, and SCLC-P with POU2F3 and SCLC-Y associated with YAP1 (7,9). Each subgroup has distinct biological implications, metastatic proclivity and classification of a patient's tumor as one of these subgroups may serve as a biomarker defining vulnerability to novel therapies. More recently, Gay et al. identified a new SCLC-I or "inflamed" subgroup, with elevated expression of immune markers. In a retrospective correlative analysis, the SCLC-I subgroup also showed potential benefit from chemotherapy combined with PD-L1 blockade (6). The study also showed that SCLC-A cell lines have enhanced sensitivity to BCL2 inhibitors, SCLC-P cell lines show enhanced sensitivity to PARP inhibitors and antimetabolite, SCLC-N cells may be sensitive to Aurora kinase inhibitors, and SCLC-I may be sensitive to BTK inhibitors (6). However, further validation in larger clinical cohorts and prospective trials are needed to confirm the clinical utility of these subtypes. Recent evidence also suggests that SCLC-N may also be particularly sensitive to the neuroendocrine specific oncolytic virus SVV-001, given upregulation of the receptor for viral entry TEM8 (10). The study by Febres-Aldana et al. (11) highlights an important novel subgroup of SCLC, defined by proficiency of the tumor suppressor RB, with increased sensitivity to CDK4/6 inhibitors. This paper is important for several reasons (1) defining a distinct subgroup of SCLC and a potential treatment option (2) characterizing RB proficient SCLC and its defining features including aggressive clinical course and association with NSCLC (3) improving the technical methodology for identification of an RB proficient SCLC subgroup, through highlighting the limitations of next generation sequencing (NGS) and the potential utility of immunohistochemical (IHC) testing in this context. SCLC tumorigenesis has long been thought to be driven by dual inactivating mutations in the tumor suppressors TP53 and RB1 (12). In mouse models of SCLC inactivation of both TP53 and RB1 was necessary for development (13,14) of SCLC. However, contrary to this established model, Febres-Aldana et al. sought to identify a subgroup of SCLC with proficient RB that had not been previously well characterized. Febres-Aldana et al. examined RB expression in 208 samples from patient with de novo SCLC. They specifically excluded samples from tumors with known hist -Abstract Truncated-

oncology,respiratory system